Printer Friendly

CEPHALON AND SCHERING-PLOUGH CONTINUE RESEARCH COLLABORATION

 CEPHALON AND SCHERING-PLOUGH CONTINUE RESEARCH COLLABORATION
 WEST CHESTER, Pa., June 9 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) of West Chester, Pa., announced today that Schering- Plough Corporation (NYSE: SGP), of Madison, N.J., made a $4 million payment required to continue their collaborative agreement to develop novel therapeutics for Alzheimer's disease. Under the terms of the companies' May 1990 agreement, Schering-Plough may elect to make payments of up to a total of $20 million to Cephalon over a five-year period. The payment announced today brings the total payments made to $14 million.
 Under the collaboration, Cephalon and Schering-Plough are conducting two research programs to treat Alzheimer's disease. One program seeks to increase the endogenous production of naturally occurring growth factor proteins in the brain using small neurotrophic factor-enhancing molecules (NEMs). The second program seeks to prevent the formation of amyloid plaques characteristic of Alzheimer's disease. The amyloid (Beta-peptide) component of plaques has been shown to be toxic to neurons and may underlie the progression of the disease. The second program is focused on developing protease inhibitors that prevent the deposition of amyloid.
 "We have successfully advanced both research programs," indicated Frank Baldino Jr., president and CEO of Cephalon. "We are very excited by the progress our collaborative efforts have yielded."
 "Alzheimer's disease represents an important and difficult medical problem," said Frank Bullock, senior vice president of Schering-Plough Research Institute. "Our nerve growth and protease inhibitor projects with Cephalon are progressing very satisfactorily."
 Cephalon, Inc., founded in 1987, is a neuroscience company focusing on small-molecule therapeutics for the treatment of neurodegenerative diseases. Through a broad-based approach encompassing neurobiology, medicinal chemistry and recombinant DNA technology, Cephalon's researchers are developing novel molecules that can be administered via conventional means. The company's most advanced programs are targeting the prevention of neuronal death in disorders such as amyotrophic lateral sclerosis (ALS), stroke and Alzheimer's disease.
 -0- 6/9/92
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-545-1919, for Cephalon/
 (CEPH SGP) CO: Cephalon Inc.; Schering-Plough Corporation ST: Pennsylvania, New Jersey IN: MTC SU:


TQ-OS -- NY029 -- 8348 06/09/92 12:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:351
Previous Article:KOCH FINANCIAL ACQUIRES ASSETS OF CHRYSLER CAPITAL PUBLIC FINANCE CORP.
Next Article:GAS PRICE UP NEARLY 2 CENTS IN ONE WEEK, AAA REPORTS
Topics:


Related Articles
SCHERING-PLOUGH TO LICENSE EPILEPSY DRUG FROM CARTER-WALLACE FOR MARKETING OVERSEAS
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON ANNOUNCES SECOND QUARTER 1992 FINANCIAL RESULTS
SCHERING-PLOUGH, NEUROGEN IN AGREEMENT TO DEVELOP NEURO-PSYCHIATRIC DRUGS
CEPHALON AND SCHERING-PLOUGH RENEW ALZHEIMER'S DISEASE RESEARCH COLLABORATION
Cephalon and Schering-Plough Conclude Alzheimer's Disease Research Collaboration
Pharmacopeia achieves second milestone in program with Schering-Plough.
Pharmacopeia forms new research collaboration with Schering Plough.
Therapeutic candidate identified through Pharmacopeia collaboration enters development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters